Riad Sherif
Chief Executive Officer chez OCULIS HOLDING AG
Fortune : 11 M $ au 31/03/2024
Profil
Riad Sherif is the founder of XPND Medical SA, which was founded in 2016.
He is currently the Chief Executive Officer & Director at Oculis SA, Oculis Holding AG, and Nexmed Plus SA. He is also an Independent Director at Revenio Group Oyj since 2022.
In his former positions, he served as the President & CEO-EMEA region at Alcon Finland OY, Director at European Biotech Acquisition Corp., President-Latin America Region at Novartis Corp., and Country Manager at Sanofi-Aventis Algérie SpA.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OCULIS HOLDING AG
2,40% | 31/12/2023 | 878 486 ( 2,40% ) | 11 M $ | 31/03/2024 |
Postes actifs de Riad Sherif
| Sociétés | Poste | Début |
|---|---|---|
| REVENIO GROUP OYJ | Director/Board Member | 08/04/2022 |
| OCULIS HOLDING AG | Chief Executive Officer | 01/12/2017 |
Oculis SA
 Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Chief Executive Officer | 01/01/2017 |
| XPND Medical SA | Founder | 01/01/2016 |
Anciens postes connus de Riad Sherif
| Sociétés | Poste | Fin |
|---|---|---|
| EURO BIOT | Director/Board Member | - |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| Sanofi-Aventis Algérie SpA | Corporate Officer/Principal | - |
| Alcon Finland OY | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| REVENIO GROUP OYJ | Health Technology |
| OCULIS HOLDING AG | Health Technology |
| Entreprise privées | 6 |
|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
| Alcon Finland OY | |
| Sanofi-Aventis Algérie SpA | |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Commercial Services |
European Biotech Acquisition Corp.
 European Biotech Acquisition Corp. Financial ConglomeratesFinance European Biotech Acquisition Corp. is a blank check company which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on January 8, 2021 and is headquartered in Lausanne, Switzerland. | Finance |
| XPND Medical SA |
